Pharma Lynx, LLC

Belkins
At Pharma Lynx, we emphasize long-term, value added relationships with a commitment to understand our customer’s business needs. By leveraging proven industry expertise, we concentrate on providing comprehensive Clinical Trials & Data Management Services to the pharmaceutical, biotechnology, generic drug, and medical device companies in the areas of Oncology, Central Nervous System (CNS), Infectious Disease & Vaccines therapeutic areas. Services Offered by Pharma Lynx: - Clinical Development Plan - Site selection - Clinical monitoring - Medical monitoring - Safety monitoring - Data Management/EDC - Biostatistics Analysis - What makes Pharma Lynx unique from other CROs? Data management is a core service of Pharma Lynx and a critical element of our customer value proposition. Pharma Lynx is headquartered out of Princeton, New Jersey, USA with an offshore office in Noida, India, and an exclusive partnership in Munich, Germany.

Related News

NURO’S SELF-DRIVING VEHICLES TO DELIVER PRESCRIPTIONS FOR CVS PHARMACY

Techcrunch | May 28, 2020

news image

Nuro, the autonomous robotics startup that has raised more than $1 billion from SoftBank Vision Fund, Greylock and other investors, said Thursday it will test prescription delivery in Houston through a partnership with CVS Pharmacy. The pilot, which will use a fleet of the startup’s autonomous Toyota Prius vehicles and transition to using its custom-built R2 delivery bots, is slated to begin in June. The partnership marks Nuro’s expansion beyond groceries and into healthcare. L...

Read More

BUSINESS INSIGHTS

GLAUKOS ANNOUNCES LICENSING AGREEMENT WITH ATTILLAPS HOLDINGS, INC.

Glaukos | September 20, 2021

news image

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a licensing agreement with Attillaps Holdings, Inc. under which Attillaps has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Attillaps’ proprietary library of investigational pharmaceutical compounds that target the eradicatio...

Read More

MEI PHARMA TO PRESENT AT UPCOMING INVESTOR CONFERENCES IN SEPTEMBER

MEI Pharma | September 04, 2020

news image

MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the following upcoming virtual investor conferences: NETGEAR Orbi Pro WiFi 6 Tri-band Mesh System Brings the Ultimate WiFi Experience to Small Businesses MEI Pharma, Inc. (NASDAQ: MEIP) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma's portfolio of drug candidates ...

Read More

NOVAVAX, ADVANCING COVID-19 SHOT, RECRUITS ASTRAZENECA EXEC AS ITS CHIEF MEDICAL OFFICER

Fiercepharma | June 17, 2020

news image

On the heels of some big fundraising moves and in the hunt for a COVID-19 vaccine, Novavax is adding some Big Pharma experience to its executive team. Joining the company's leadership team as chief medical officer is Filip Dubovsky, an AstraZeneca veteran. Dubovsky joins Novavax directly from the British drugmaker, where he served as head of clinical engagement and policy, plus as chief medical officer for clinical affairs. Before that role, he oversaw a portfolio of more than two doze...

Read More
news image

NURO’S SELF-DRIVING VEHICLES TO DELIVER PRESCRIPTIONS FOR CVS PHARMACY

Techcrunch | May 28, 2020

Nuro, the autonomous robotics startup that has raised more than $1 billion from SoftBank Vision Fund, Greylock and other investors, said Thursday it will test prescription delivery in Houston through a partnership with CVS Pharmacy. The pilot, which will use a fleet of the startup’s autonomous Toyota Prius vehicles and transition to using its custom-built R2 delivery bots, is slated to begin in June. The partnership marks Nuro’s expansion beyond groceries and into healthcare. L...

Read More
news image

BUSINESS INSIGHTS

GLAUKOS ANNOUNCES LICENSING AGREEMENT WITH ATTILLAPS HOLDINGS, INC.

Glaukos | September 20, 2021

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a licensing agreement with Attillaps Holdings, Inc. under which Attillaps has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Attillaps’ proprietary library of investigational pharmaceutical compounds that target the eradicatio...

Read More
news image

MEI PHARMA TO PRESENT AT UPCOMING INVESTOR CONFERENCES IN SEPTEMBER

MEI Pharma | September 04, 2020

MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the following upcoming virtual investor conferences: NETGEAR Orbi Pro WiFi 6 Tri-band Mesh System Brings the Ultimate WiFi Experience to Small Businesses MEI Pharma, Inc. (NASDAQ: MEIP) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma's portfolio of drug candidates ...

Read More
news image

NOVAVAX, ADVANCING COVID-19 SHOT, RECRUITS ASTRAZENECA EXEC AS ITS CHIEF MEDICAL OFFICER

Fiercepharma | June 17, 2020

On the heels of some big fundraising moves and in the hunt for a COVID-19 vaccine, Novavax is adding some Big Pharma experience to its executive team. Joining the company's leadership team as chief medical officer is Filip Dubovsky, an AstraZeneca veteran. Dubovsky joins Novavax directly from the British drugmaker, where he served as head of clinical engagement and policy, plus as chief medical officer for clinical affairs. Before that role, he oversaw a portfolio of more than two doze...

Read More